Allogeneic Mesenchymal Stromal Cell Injection to Alleviate Ischemic Heart Failure Following Arterial Switch Operation

Filippo Rapetto; Demetris Taliotis; Qiang Chen; Iakovos Ttofi; Dominga Iacobazzi; Paolo Madeddu; Serban C Stoica; Ben Weil; Mark W Lowdell; Massimo Caputo

doi:10.1016/j.jaccas.2021.02.039

Allogeneic Mesenchymal Stromal Cell Injection to Alleviate Ischemic Heart Failure Following Arterial Switch Operation

JACC Case Rep. 2021 May;3(5):724-727. doi: 10.1016/j.jaccas.2021.02.039.

Authors

Filippo Rapetto^{1

2}, Demetris Taliotis³, Qiang Chen¹, Iakovos Ttofi¹, Dominga Iacobazzi², Paolo Madeddu², Serban C Stoica¹, Ben Weil⁴, Mark W Lowdell⁴, Massimo Caputo^{1

2}

Affiliations

¹ Department of Cardiac Surgery, Bristol Heart Institute and Bristol Royal Hospital for Children, Bristol, United Kingdom.
² Translational Health Sciences, University of Bristol, Bristol, United Kingdom.
³ Department of Cardiology, Bristol Heart Institute and Bristol Royal Hospital for Children, Bristol, United Kingdom.
⁴ Centre for Cell, Gene & Tissue Therapeutics, Royal Free London NHS Foundation Trust, London, United Kingdom.

Abstract

Cell therapy is a promising tool to prevent and treat heart failure in congenital heart disease. We report the first case of intramyocardial injection of allogeneic mesenchymal stromal cells as rescue therapy in a neonate with ischemic heart failure following arterial switch procedure for isolated transposition of the great arteries. (Level of Difficulty: Advanced.).

Keywords: CHD, congenital heart disease; FAC, fractional area change; GLS, global longitudinal strain; LCA, left coronary artery; LV, left ventricular; MSC, mesenchymal stromal cell; acute heart failure; coronary vessel anomaly; transposition of the great arteries.

Publication types

Case Reports

Abstract

Publication types

Grants and funding